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Students’ Corner
Maximum tolerable dose of Cyclophosphamide and Azathioprine in Pakistani
Patients with Primary Renal Disease
S. S. Ali*, M. A. Rabbani, S. S. M. Moinuddin*, S. Virani*, F. Farooque, A. Salam, A. Ahmad
Medical Students*, Department of Medicine, The Aga Khan University Hospital, Karachi.

Abstract
Objective: The immunosuppressive regimens, at present, mainly rely on western guidelines that
were derived from studies conducted in western populations. No such study exists for South Asian
population, which is home to almost two billion people different in both genetics and environment from
west. Locally derived thresholds for side effects markedly different from western figures may warrant
re-adjustment of current local immunosuppressive regimens that are at present based largely on
western guidelines. In order to define optimum dose for Cyclophosphamide (CYC) and Azathioprine
(AZA) based immunosuppressive therapy, we conducted this study to find out maximum tolerable
doses of azathioprine (AZA) and cyclophosphamide (CYC) beyond which neutropenia and
thrombocytepenia are most likely to occur in patients with primary renal pathology.
Method: Patients with systemic vasculitis and idiopathic glomerulonephritis who were on CYC and AZA were
identified through review of medical records at a tertiary care hospital in Pakistan (The Aga Khan University
Hospital, Karachi). Patients were categorized under three principal diagnosis i.e. systemic lupus erythematosus
(SLE), primary (idiopathic) glomerulonephritis (GN) and Wegener's granulomatosis (WG). The Receiver
Operating Curve (ROC) was used to calculate the maximum tolerable dose for both CYC and AZA.
Results: We identified 94 patients aged 6-82 years (median 44.5 years) with primary renal disease (Wegener's
granulomatosis n=13, Systemic lupus erythematosis n=62 and idiopathic glomerulonephritis n=19) who received
CYC or AZA. Of these 94 patients, 36.2% (n=34) received CYC and 63.8% (n=60) received AZA. The mean dose
of CYC was 1.54 ± 0.50 mg/kg of body weight (range: 0.77-2.93). The mean dose of AZA was 1.64± 0.59 mg/kg
of body weight (range: 0.47-2.97). The maximum tolerable doses calculated for CYC and AZA were 1.25 mg/kg
and 1.30 mg/kg of body weight respectively. The maximum tolerable dose for CYC and AZA among males could
not be calculated, because of insufficient number of patients who developed neutropenia and thrombocytopenia.
The maximum tolerable doses for CYC and AZA among females were 1.34 mg/kg and 1.03 mg/kg of body weight
respectively. Also we found out that AZA was relatively more likely to cause neutropenia and thrombocytopenia
(p = 0.07).
Conclusion: We thereby recommend that CYC should be initiated at a dose no more than 1 mg/kg of body
weight and AZA at an initial dose of 0.75-1.0 mg/kg of body weight. The dose may be adjusted later on the basis
of clinical response and laboratory reports (JPMA 54:39;2004).

Introduction
Connective tissue disorders, vasculitides and
autoimmune diseases are but a few of many chronic
conditions afflicting the population. For the aforementioned
set of conditions, treatment lies largely in the use of
immunosuppressives, such as Cyclophosphamide (CYC)
and Azathioprine (AZA). Unfortunately, these medications
are not without side effects. Though decreasing
inflammatory reactions associated with numerous
vasculitides and connective tissue diseases, they carry the
risk of bone marrow suppression that may manifest as
febrile neutropenia, thrombocytopenia, anemia and
increased susceptibility to infectious diseases.
The major determinant of such myelosuppression is
the dosage of the cytotoxic drugs given to the patient;
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however, other variables may influence the probability of
such an event.1 Oral daily CYC at a dose of 2 mg/kg body
weight/day in combination with corticosteroids, a regimen
that was introduced by Fauci et al.2, resulted in a steep
increase in the survival rate for vasculitic and connective
tissue disease and a reduction in vasculitic organ damage;
however, it also caused substantial treatment-associated
morbidity.3-6 Haubitz et al.7 in their study also used oral
CYC at dose of 2 mg/kg body weight and sixty percent of
their patients developed at least one episode of leukopenia;
thrombocytopenia was seen in 12% of those patients.
Brown et al.8 used Azathioprine in the range of 1.3-2.7
mg/kg of body weight/day. They followed up all patients for
a minimum of 2 years. Adverse effects occurred in 10 out of
13 patients. Although mild, these effects warranted a
reduction in the dose of AZA. An oral dose of 2 mg/kg/day
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of AZA was used by Cattan et al.9 A significant decrease in
blood leukocytes and neutrophils was noted after a month of
therapy that further declined after the first year of treatment.
Current immunosuppressive regimens are based on
western guidelines, which may or may not be truly
applicable to the local South Asian population. It may be,
therefore, more feasible to adjust therapeutic guidelines on
the basis of locally derived figures than from those derived
through similar studies carried out in the west.

Patients and Methods
Patients
with
systemic
vasculitis
and
glomerulonephritis who were on CYC and AZA were
identified through review of medical records at a tertiary
care hospital in Pakistan (The Aga Khan University
Hospital, Karachi Pakistan). We categorized primary renal
disease under three principal diagnosis i.e. Systemic lupus
erythematosus (SLE), glomerulonephritis (GN) and
Wegener's granulomatosis (WG). The definitions on which
these categories are based have been described in
literature.10-13 The diagnosis in each patient had been
established by clinical and histological evidence of
vasculitis and glomerulonephritis. A complete blood count
had been done before initiation of immunosuppressive
therapy and was repeated after one month. The maximum
tolerable dose (the dose at which leukopenia or
thrombocytopenia or both occurred) was evaluated by blood
count at one month. Leukopenia was defined as total
leukocyte count less than 3.8x109/L of blood; neutropenia
was defined as absolute neutrophilic count (ANC) less than
1.5x109/L and thrombocytopenia was defined as platelets
count less than 140x109/L of blood. The maximum tolerable
dose was defined as that dose beyond which leucopenia or
thrombocytopenia or both occurred, warranting reduction of
dose of the immunosuppressive drug. In all patients the
status of leukopenia and thrombocytopenia had been
confirmed by repeated complete blood counts. The
cytotoxicity of immunosuppressive drugs was confirmed by
clearly improving blood pictures following reduction of the
respective doses of CYC and AZA.
Results were expressed as mean ± standard deviation
and median with range. Univariate analysis was done by
using Independent Sample t-test, Mann-Witney U test,
Pearson Chi-square and Fisher-exact-test, wherever
appropriate. A p-value less than 0.05 was considered
statistically significant. All p-values were two sided. The
Receiver Operating Curve (ROC) was used to calculate the
maximum tolerable dose for both CYC and AZA. In ROC
curve the true positive rate (sensitivity) is plotted in function
of the false positive rate (1.0 - specificity) for different cutoff points. Each point on the ROC plot represents a
sensitivity/specificity pair corresponding to a particular
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decision threshold.

Results
Ninety-four patients were identified with systemic
vasculitis and glomerulonephritis with documented renal
involvement who had received CYC or AZA. Out of these
94 patients, 30.9% (n=29) were male and 69.1% (n=65)
were female. The mean age of patients was 35.6 ± 16.2
years (median 44.5 years; range 6-82 years). Of these 94
patients, 36.2% (n=34) received CYC and 63.8% (n=60)
received AZA. The mean dose of CYC was 1.54 ± 0.50
mg/kg of body weight (range: 0.77-2.93). The mean dose of
AZA was 1.64 ± 0.59 mg/kg of body weight (range: 0.472.97). Out of 94 patients, WG was present in 13.8% (n=13),
SLE in 66.0% (n=62) and idiopathic GN in 20.2% (n=19).
The number of patients who received CYC and AZA in our
three-principle diagnoses is shown in the Table.
Table. Disease and drug distribution of patients.
SLE

GN

WG

Total

CYC

14

11

9

34

AZA

48

8

4

60

Total

62

19

13

94

CYC: Cyclophosphamide
AZA: Azathioprine
GN: Primary (Idiopathic) Glomerulonephritis
WG: Wegener's Granulomatosis
SLE: Systemic Lupus Erythematosus

Of the patients who received CYC (n=34), 47.0%
(n=16) were male and 53.0% (n=18) were female. Of these
16 male patients, 6.2% (n=1) developed both neutropenia
and thrombocytopenia. Amongst the 18 females who
received CYC, 38.8% (n=7) developed neutropenia and
thrombocytopenia.
Of the patients who received AZA (n=60), 21.7%
(n=13) were male and 78.3% (n=47) were female. Of these
13 males, 30.7% (n=4) developed neutropenia and
thrombocytopenia. Of the 47 females, 44.7% (n=21)
developed neutropenia and thrombocytopenia.
We calculated the dose at which the probability of
developing neutropenia and thrombocytopenia was most
likely to occur by using the ROC curve. The cut off
calculated for CYC as a whole group was 1.25 mg/kg body
weight (sensitivity = 88.8% and specificity = 65.2%). The
cut off for AZA as a whole group was 1.30 mg/kg body
weight (sensitivity = 68.0% and specificity = 60.7%). The
cut off for CYC and AZA among males could not be
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calculated, as there were insufficient number of patients
(one and four respectively) who developed neutropenia and
thrombocytopenia. The cut off for CYC among females was
1.34 mg/kg of body weight (sensitivity = 71.4% and
specificity = 54.8%). The cut off for AZA among females
was 1.03 mg/kg of body weight (sensitivity = 74.6% and
specificity = 56.7%). AZA was more likely than CYC to
cause neutropenia and thrombocytopenia (p value = 0.07).

Discussion
Immunosuppression with Cyclophosphamide (CYC)
and Azathioprine (AZA) is the standard treatment for
connective tissue diseases and vasculitides. It is frequently
complicated by life threatening febrile neutropenia. Though
less frequent, thrombocytopenia with superimposed anemia
can significantly worsen a patient's quality of life. Although
controlled lowering of leukocyte count into a low normal
range by CYC and AZA appears to enhance the therapeutic
effect, lower leukocyte counts are a definite risk factor for
contracting infections. Guillevin et al observed major
infections in 69.6% in a cohort of patients having
vasculitides receiving daily oral CYC.5 A major proportion
of such events were associated with leukopenia.6 However,
infections did not occur in our patients as most cases that
developed mild or moderate leukopenia due to CYC and
AZA treatment reverted within a few days of decreasing the
dose or withholding CYC and AZA. On the other hand,
severe neutropenia, i.e., ANC below 1,000/ul, tends to be
more protracted.6 The experience with cytotoxic treatment
is that the risk of infectious complications increases sharply
when the ANC drops below this threshold, and the risk
increases progressively with longer duration of severe
neutropenia.14
As of yet there are no firm guidelines on the dose or
optimum duration of treatment with CYC and AZA. Daily
oral CYC at a dosage of 2mg/kg body weight/day resulted
in a steep increase in the survival rate for vasculitic and
connective tissue disease and a reduction in vasculitic organ
damage2; however, it also caused substantial treatmentassociated morbidity.3-6 Haubitz et al. in their study also
used oral 2mg/kg body weight CYC and sixty percent of
their patients developed at least one episode of leukopenia;
thrombocytopenia was seen in 12% of those patients.7
Brown et al. used Azathioprine in the range of 1.3-2.7
mg/kg of body weight/day.8 They followed up all patients
for a minimum of 2 years. Adverse effects occurred in 10
out of 13 patients. Although mild, these effects warranted a
reduction in the dose of AZA. An oral dose of 2 mg/kg/day
of AZA was used by Cattan et al.9 A significant decrease in
blood leukocytes and neutrophils was noted after a month of
treatment that further declined at the end of first year of
treatment.9 Contrary to these studies, neutropenia and
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thrombocytopenia occurred in our patients at lower doses.
Administration of CYC and AZA not only has both
mutagenic and marrow suppressive potential but can induce
remissions in numerous severe chronic connective tissue
disorders. The severity of such side effects warrants
research to derive doses at which the most beneficial trade
off between treatment versus risk can be seen. Studies done
in the west have attempted to derive such doses.
Unfortunately such values cannot be easily applied to the
larger segment of the world's population hence there is
requirement for the doses to be separately derived for
communities with different genetic backgrounds,
environments and other such variables. Such 'variables' may
not only affect the dose at which the said drugs' benefit
might be seen but also the threshold at which adverse effects
begin to manifest.

Conclusion
Based on our findings we recommend that CYC
should be initiated at a dose no more than 1 mg/kg of body
weight and AZA at an initial dose of 0.75 - 1mg/kg of body
weight to minimize risk of neutropenia and
thrombocytopenia while continuing to provide an effective
therapeutic dose. The dose can later be adjusted on grounds
of clinical response and laboratory results.
By deriving such figures, we find maximum
tolerable dose of the mentioned immunosuppressive drugs
to be different from figures derived in western studies
thereby suggesting that current immunosuppressive
regimens (based largely on western guidelines) may need
adjustment to better suit the local South Asian population.
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Letter to the Editor
Potential role of Moxifloxacin in Methicillin-Resistant Staphylococcus aureus
(MRSA) Infections
Madam, Staphylococcus aureus is the commonest
isolate in clinical practice. Over the years it has acquired
resistance to almost all the available antimicrobials and
emergence of multi-drug resistant methicillin-resistant
Staphylococcus aureus (MRSA) has been especially
troublesome. MRSA now accounts for a major proportion of
Staphylococcus aureus infections worldwide. The
antimicrobials of choice for treatment of MRSA infections
are the glycopeptides, vancomycin and teicoplanin.1 These
drugs however are expensive, carry significant side effects,
and their uncontrolled use can lead to development of
resistance against them. Indeed, such resistance is now
being increasingly reported from all over the world.1,2 This
has led to the search for other drugs for treatment of MRSA
infections. Several new drugs have been introduced recently
including quinupristin-dalfopristin, the oxazolidinones and
the fourth generation quinolones such as moxifloxacin. We
retrospectively studied the in vitro efficacy of moxifloxacin
against clinical isolates of MRSA.
According to our computerized database, the
frequency of MRSA among all nosocomial isolates of
Staphylococcus aureus at the Armed Forces Institute of
Pathology (AFIP), Rawalpindi was 51% (516/1018) in the
first nine months of 2003. Most of the MRSA isolates were
from pus and pus swabs (n=394), while the rest were from
blood (n=37), intravenous catheter tips and surgical
drainage tubes (n=31), various body fluid (n=19),
respiratory specimens (n=18) and others (n=17).
Antimicrobial susceptibility of the isolates was
tested by the modified Kirby-Bauer disk diffusion technique
and results were interpreted according to the National
Committee for Clinical Laboratory Standards (NCCLS)
criteria.3 Susceptibility to moxifloxacin was tested by using
5µg moxifloxacin disk (Oxoid) on Mueller-Hinton agar
incubated at 370C overnight while methicillin-resistance was
tested by using 1 µg oxacillin disk (Oxoid) on MuellerHinton agar containing 4% sodium chloride incubated at 330
C for 24 hours. Our results were quite encouraging: 444
isolates (86%) were susceptible to moxifloxacin while 72
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(14%) were resistant.
The latest generation of fluoroquinolones like
moxifloxacin, an 8-methoxyfluoroquinolone have broad
antibacterial activity against both Gram-positive and Gramnegative organisms. They have enhanced bactericidal activity
as well as decreased cross-resistance with other quinolones.
Moxifloxacin is now being recommended for use against
Gram-positive pathogens especially Streptococcus
pneumoniae.4 However its role against Staphylococcus
aureus has not been properly evaluated although data
suggests that it has good in vitro as well as in vivo activity
against MRSA with a low propensity to select for resistance.5
Our data has shown excellent in vitro activity of
moxifloxacin against MRSA. However a resistance rate of
14% despite the drug's recent introduction is worrisome. It
is yet to be seen if drug resistance in moxifloxacin would
spread as rapidly as in other quinolones. The drug might
have a useful role in selected cases of MRSA infections
such as patients with renal insufficiency. If its efficacy in
vivo is validated by clinical trials, then with its lesser side
effects, moxifloxacin might be a cost-effective alternative to
vancomycin in MRSA infections.
T. Butt, R. N. Ahmad, M. Usman
Department of Microbiology, Armed Forces
Institute of Pathology, Rawalpindi
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